Skip to content

Study on the Role of the Immunopathological Mechanism Driven by TIF1-? Self-Antigen in the Pathogenesis of Dermatomyositis

Study on the Role of the Immunopathological Mechanism Driven by TIF1-? Self-Antigen in the Pathogenesis of Dermatomyositis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121244
Enrollment
Unknown
Registered
2026-03-27
Start date
2026-03-27
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatomyositis

Interventions

The group with negative TIF1-? antibody test result:None
The group with positive TIF1-? antibody observation:None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with DM who have been clearly diagnosed according to the Bohn/Peter criteria; diagnosed with malignant tumors based on clinical, imaging or pathological evidence, and meeting the diagnostic criteria for all types of tumors; 2. The diagnosis of malignant tumors occurred within 3 years before or after the onset of DM; 3. Tumor paraffin specimens, blood samples and muscle tissues can be obtained; 4. Age range: 18-75 years old, gender not restricted.

Exclusion criteria

Exclusion criteria: 1. Include other connective tissue diseases (such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome); 2. Severe liver and kidney dysfunction (Child-Pugh grade B or C, creatinine >= 1.5 times the upper limit of normal)

Design outcomes

Primary

MeasureTime frame
The relationship between TIF1-? gene mutation and cross-immune response;

Countries

China

Contacts

Public ContactYang Kanbo

China-Japan Friendship Hospital

hanbo_yang@126.com+86 10 84205566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026